Explore

Regeneron and Parabilis Collaborate on $2.3 Billion Antibody-Peptide Conjugate Development

Regeneron and Parabilis Collaborate on $2.3 Billion Antibody-Peptide Conjugate Development

Regeneron and Parabilis Collaborate on $2.3 Billion Antibody-Peptide Conjugate Development

Regeneron drops after skin cancer treatment fails late-stage trial

Regeneron drops after skin cancer treatment fails late-stage trial

By Christy Santhosh May 18 (Reuters) - Regeneron's shares fell 12% in morning trade on Monday after the company's experimental treatment missed the main goal in a late-stage trial for patients with a type of skin cancer.

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

CEL-SCI Reports Progress in Multikine Development and Financial Results

CEL-SCI Reports Progress in Multikine Development and Financial Results

CEL-SCI Reports Progress in Multikine Development and Financial Results

Halia Therapeutics Expands Board with New Executive Chairman and Directors to Drive Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors to Drive Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors to Drive Growth

FDA Accepts sNDA and Grants Priority Review to AQNEURSA for Ataxia-Telangiectasia

FDA Accepts sNDA and Grants Priority Review to AQNEURSA for Ataxia-Telangiectasia

FDA Accepts sNDA and Grants Priority Review to AQNEURSA for Ataxia-Telangiectasia

Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial

Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial

Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial

Akari Therapeutics Reports Increased Net Loss in Q1 2026 Amid Pre-Revenue Status

Akari Therapeutics Reports Increased Net Loss in Q1 2026 Amid Pre-Revenue Status

Akari Therapeutics Reports Increased Net Loss in Q1 2026 Amid Pre-Revenue Status

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements